In Hee Choi

In Hee Choi

Auto-generated profile, based on publicly available information

In Hee Choi

Department of Genetic Counseling, University of Ulsan College of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2018 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
EKEungu Kang
Eungu Kang
YKYoon-Myung Kim
Yoon-Myung Kim
MKMinji Kang
Minji Kang
SHSun-Hee Heo
Sun-Hee Heo
GKGu-Hwan Kim
Gu-Hwan Kim
BLBeom Hee Lee
Beom Hee Lee
Fatty acid oxidation disorders (FAODs) include more than 15 distinct disorders with variable clinical manifestations. After the introduction of newborn screening using tandem mass spectrometry, early identification of FAODs became feasible. This study describes the clinical, biochemical and molecular characteristics of FAODs patients detected by newborn screening (NBS) compared with those of 9 patients with symptomatic presentations. Clinical and genetic features of FAODs patients diagnosed by NBS and by symptomatic presentations were reviewed. Fourteen patients were diagnosed with FAODs by NBS at the age of 54.8 ± 4.8 days: 5 with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, 5 with medium chain acyl-CoA dehydrogenase (MCAD) deficiency, 1 with primary carnitine deficiency, 1 with carnitine palmitoyltransferase 1A (CPT1A) deficiency, 1 with long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein (LCAHD/MTP) deficiency, and 1 with short chain acyl-CoA dehydrogenase (SCAD) deficiency. Three patients with VLCAD or LCHAD/MTP deficiency developed recurrent rhabdomyolysis or cardiomyopathy, and one patient died of cardiomyopathy. The other 10 patients remained neurodevelopmentally normal and asymptomatic during the follow-up. In 8 patients with symptomatic presentation, FAODs manifested as LCHAD/MTP deficiencies by recurrent rhabdomyolysis or cadiomyopathy (6 patients), and VLCAD deficiency by cardiomyopathy (1 patient), and CPT1A deficiency by hepatic failure (1 patient). Two patients with LCHAD/MTP deficiencies died due to severe cardiomyopathy in the neonatal period, and developmental disability was noted in CPT1A deficiency (1 patient). NBS helped to identify the broad spectrum of FAODs and introduce early intervention to improve the clinical outcome of each patient. However, severe clinical manifestations developed in some patients, indicating that careful, life-long observation is warranted in all FAODs patients.

18 December 2020 in Medicine
Verified
Journal Article
Open access
HAHyunji Ahn
Hyunji Ahn
GSGo Hun Seo
Go Hun Seo
AOArum Oh
Arum Oh
YLYena Lee
Yena Lee
CKChangwon Keum
Changwon Keum
ICIn Hee Choi
In Hee Choi
Schaaf-Yang syndrome (SYS) is a recently identified disorder caused by a loss-of-function mutation in a maternally imprinted gene, MAGEL2, at 15q11.2q13. Due to its extreme rarity and wide range of clinical severity, clinical suspicion is difficult for a physician. In the current study, its frequency among the Korean pediatric patients with developmental delay (DD) or intellectual disability (ID) was assessed. As the first report of Korean patients with SYS, our study aims to increase the awareness of this condition among the physicians taking care of the pediatric patients with DD/ID and hypotonia. The patients diagnosed with SYS by whole-exome sequencing (WES) among the 460 Korean pediatric patients with DD/ID were included, and their clinical and molecular features were reviewed. Four patients (0.9%) were diagnosed with SYS. Profound DD (4 patients), multiple anomalies including joint contractures and facial dysmorphism (4 patients), generalized hypotonia (3 patients), and severe respiratory difficulty requiring mechanical ventilation (3 patients) were noted in most cases, similar to those in previous reports. Sleep apnea (2 patients), autistic features (2 patients), a high grade of gastroesophageal reflux (1 patient), and seizures (1 patient) were found as well. A total of 3 different truncating MAGEL2 mutations were identified. A previously-reported mutation, to be the most common one, c.1996dupC, was found in 2 patients. The other 2 mutations, c.2217delC and c.3449_3450delTT were novel mutations. As MAGEL2 is maternally imprinted, 2 patients had inherited the MAGEL2 mutation from their respective healthy fathers. SYS is an extremely rare cause of DD/ID. However, hypotonia, joint contractures, profound DD/ID and facial dysmorphism are the suggestive clinical features for SYS. As a maternally imprinted disorder, it should be reminded that SYS may be inherited in form of a mutation from a healthy father.

17 February 2021 in Genes
Verified
Journal Article
Open access
PDF file
YLYeonmi Lee
Yeonmi Lee
TKTaeho Kim
Taeho Kim
MLMiju Lee
Miju Lee
Seongjun SOSeongjun SO
Seongjun SO
MKMustafa Zafer Karagozlu
Mustafa Zafer Karagozlu
BLBeom Hee Lee
Beom Hee Lee
Defects in the mitochondrial genome (mitochondrial DNA (mtDNA)) are associated with both congenital and acquired disorders in humans. Nuclear-encoded DNA polymerase subunit gamma (POLG) plays an important role in mtDNA replication, and proofreading and mutations in POLG have been linked with increased mtDNA deletions. SSBP1 is also a crucial gene for mtDNA replication. Here, we describe a patient diagnosed with Pearson syndrome with large mtDNA deletions that were not detected in the somatic cells of the mother. Exome sequencing was used to evaluate the nuclear factors associated with the patient and his family, which revealed a paternal POLG mutation (c.868C > T) and a maternal SSBP1 mutation (c.320G > A). The patient showed lower POLG and SSBP1 expression than his healthy brothers and the general population of a similar age. Notably, c.868C in the wild-type allele was highly methylated in the patient compared to the same site in both his healthy brothers. These results suggest that the co- deficient expression of POLG and SSBP1 genes could contribute to the development of mtDNA deletion.

22 August 2024 in Journal of Genetic Counseling
Verified
Journal Article
Open access
SYSojin Yang
Sojin Yang
YCYoon Jung Chang
Yoon Jung Chang
KKKyung Ok Kim
Kyung Ok Kim
BLBeom Hee Lee
Beom Hee Lee
SKSun‐Young Kong
Sun‐Young Kong
ICIn Hee Choi
In Hee Choi
The Genetic Counseling Outcome Scale (GCOS‐24) was developed to measure patient‐reported outcomes to evaluate the effectiveness of genetic counseling and testing services. In the current study, the Korean version of GCOS (K‐GCOS) was developed to reflect the sociocultural characteristics of Korea, and its clinical applicability was assessed. Overall, 231 Koreans, including patients with genetic diseases and their family members, participated and completed the K‐GCOS, Hospital Anxiety and Depression Scale (HADS), Multidimensional Health Locus of Control (MHLC) scale, and Satisfaction with Life Scale (SWLS). Validity was examined by assessing the correlations between K‐GCOS scores and other relevant scale scores. Reliability was confirmed using Cronbach's alpha and test–retest scores, measured over 2 weeks. We performed exploratory factor analysis of the five structures of GCOS‐24. For K‐GCOS, four‐factor structures were identified: “cognitive–behavioral control,” “uncertainty about control,” “hope,” and “emotional regulation.” Four original GCOS‐24 items were removed because of low factor loadings and small inter‐item correlations. K‐GCOS‐20 scores were positively correlated with SWLS (r = 0.456) and MHLC‐internal (r = 0.213) scores but negatively correlated with HADS (anxiety r = −0.428, depression r = −0.469) and MHLC‐internal (r = −0.278) scores. These findings demonstrate that K‐GCOS‐20 is a reliable and valid tool for evaluating genetic counseling services in Korea.

25 February 2025 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
DKDohyung Kim
Dohyung Kim
JYJi-Hee Yoon
Ji-Hee Yoon
HBHyunwoo Bae
Hyunwoo Bae
SHSoojin Hwang
Soojin Hwang
GSGo Hun Seo
Go Hun Seo
BLBeom Hee Lee
Beom Hee Lee
The Verloes or Hale diagnostic criteria have been applied for diagnosing CHARGE syndrome in suspected patients. This study was conducted to evaluate the diagnostic rate of CHD7 according to these diagnostic criteria in suspected patients and also to investigate other genetic defects in CHD7-negative patients. The clinical findings and the results of genetic testing of CHD7, chromosome microarray, exome sequencing, or genome sequencing of 59 subjects were reviewed. CHD7 pathogenic variants were identified in 78% of 46 subjects who met either the Verloes or Hale diagnostic criteria and in 87% of 38 subjects who met both criteria, whereas no CHD7 variant was detected in 13 subjects who met neither criterion. Among 23 patients without the CHD7 variant, six genetic diseases were identified in 7 patients, including Wolf–Hirschhorn syndrome, 1q21 deletion syndrome, 19q13 microdeletion, and pathogenic variants in PLCB4, TRRAP, and OTX2. Based on these comprehensive analyses, the overall diagnostic rate was 73% for seven different genetic diseases. This study emphasizes the importance of comprehensive clinical and genetic evaluation in patients with clinically suspected CHARGE syndrome, recognizing the overlapping phenotypes in other rare genetic disorders.

20 May 2024 in Journal of Genetic Counseling
Verified
Journal Article
Open access
ICIn Hee Choi
In Hee Choi
YKYun Kyung Kim
Yun Kyung Kim
SYSeo Yeon Yang
Seo Yeon Yang
VCVit‐Na Choi
Vit‐Na Choi
SJSu Min Ji
Su Min Ji
BLBeom Hee Lee
Beom Hee Lee
Since the 1990s, genetic clinics have been established in South Korea, enabling the provision of clinical genetics services. However, genetic counseling services are not widely used in the medical system. In contrast, recently, the demand for genetic counseling has increased due to the rapid development of genomic medicine. Therefore, it is important for medical geneticists and genetic counselors to collaboratively provide genetic counseling services. This study aimed to evaluate the perception and satisfaction of patients with rare genetic diseases and their families regarding genetic counseling services provided by a genetics team at the medical genetics center of a tertiary general hospital for rare genetic diseases. From April to November 2021, a survey was conducted with 203 individuals, including 111 and 92 individuals in the patient and family groups, respectively. Overall, 164 individuals (80.8%) responded that they were aware of genetic counseling services, and 135 individuals (66.5%) responded that they were aware of the role of genetic counselors. Patients and their families wanted to receive information about the following from genetic counseling: clinical manifestation and prognosis of the diagnosed disease (78.8%), treatment and management of the disease (60.6%), risk of recurrence within the family (55.7%), treatment options and alternatives for family and prenatal testing, and various support services. The score of satisfaction with genetic counseling services provided by the genetics team was 8.19 ± 1.68 out of 10. Patients with rare genetic diseases and their families were satisfied with genetic counseling services regarding their diseases, test results, and treatment options. Moreover, the patients could receive psychosocial support and referrals to other medical service providers and support services. As a genetic team approach, collaboration between medical geneticists and certified genetic counselors would be useful in providing information and in diagnosing, treating, and managing patients.